Early-Stage IVD Consulting FAQs:

Feasibility, Troubleshooting, and Development Strategy

Understanding Early-Stage IVD Development

  • An early-stage IVD consultant evaluates whether an assay is technically viable, identifies key risks, and provides clear “go / refine / stop” recommendations before full development begins.

  • Assay feasibility is the assessment of whether an assay can realistically achieve required analytical performance, including sensitivity, specificity, and reproducibility-under practical conditions.

  • Feasibility assessment determines whether an assay can realistically achieve the required analytical performance.

    This involves evaluating the detection mechanism, reagent and bioconjugation strategy, expected sensitivity and specificity, and potential sources of variability, to support clear “go / refine / stop” decisions.

  • Early data should demonstrate basic assay functionality and performance potential.

    This typically includes preliminary evidence of sensitivity, specificity, and reproducibility, along with an understanding of key variables influencing assay behaviour.

When & Why to Engage a Consultant

  • Engage when feasibility is unclear, assay performance is inconsistent, or early data does not support confident technical decisions, particularly before investment, scale-up, or key development milestones.

  • The highest impact is at key decision points: before investment or due diligence, prior to tech transfer or scale-up, and when performance issues begin to stall development.

  • External expertise is valuable when data is unclear, inconsistent, or difficult to interpret.

    Independent input helps ensure decisions are based on robust technical evaluation.

  • An independent consultant provides objective evaluation and identifies hidden risks early.

    This supports clearer decisions and reduces costly downstream rework.

Assay Challenges & Troubleshooting

  • Yes. ORIVISE applies structured root-cause analysis to identify the underlying drivers of variability, instability, or poor performance, and defines a focused, decision-driven path forward.

  • Assay variability is usually driven by underlying system instability rather than a single issue.

    Common causes include inconsistent bioconjugation, reagent instability, and poorly controlled assay conditions.

  • High background signal is typically due to non-specific interactions.

    This often results from inadequate blocking, non-specific binding, or suboptimal assay design.

  • Common issues include inconsistent coupling efficiency, loss of biological activity, and instability over time.

    These directly impact assay sensitivity and reproducibility.

  • Reproducibility improves by identifying and controlling key variables.

    This includes optimising reagent stability, standardising conditions, and defining critical parameters.

  • In diagnostics, technical debt arises when data is generated without a clear decision framework. It often appears manageable in early stages but leads to issues during scale-up, transfer, or regulatory review.

    Orivise identifies and reduces these risks early to prevent costly rework.

Development & Scale-Up Readiness

  • The assay must demonstrate consistent performance and defined critical parameters.

    Reagent stability, reproducibility, and controlled conditions are essential before transfer.

  • Failures typically occur when early-stage variability or instability has not been addressed.

    Small-scale performance often does not translate without controlled processes.

  • An assay is development-ready when it shows stable, reproducible performance and clearly defined parameters.

    Performance characteristics must be consistently achievable.

How ORIVISE Works

  • ORIVISE provides independent technical evaluation and decision support, not laboratory execution.

    While CROs generate data, Orivise focuses on ensuring the right questions are being answered and that decisions are based on robust technical foundations before resources are committed.

  • No. ORIVISE provides independent advisory support and technical decision-making input rather than laboratory execution.

    This ensures all recommendations remain unbiased and focused on what is technically and commercially viable.

  • Outputs may include a technical risk summary, feasibility assessment, evidence-gap review, development-readiness report, due diligence memo or prioritised action plan.

  • ORIVISE primarily supports immunoassays, including ELISA and particle-based systems, with a focus on early-stage feasibility, performance evaluation, and optimisation.

    This approach extends across a broader range of diagnostic platforms, including point-of-care and biosensor-based systems.

  • ORIVISE supports start-ups, early-stage diagnostics teams, and established organisations requiring focused technical input at critical decision points.

  • ORIVISE provides independent technical due diligence, assessing assay design, data quality, and underlying risks to ensure scientific claims are robust and defensible before investment decisions are made.

  • ORIVISE focuses on early-stage feasibility and technical decision-making, where most development risk is created.

    The approach is independent and decision-led, ensuring the right questions are addressed before resources are committed.

  • Yes. ORIVISE can review technical data room materials to identify red flags, unsupported claims, missing evidence and questions that investors should raise before making funding decisions.

  • ORIVISE can provide technical and commercialisation input for grant-led diagnostic translation, including feasibility planning, evidence-gap analysis, risk framing and development-readiness review.

Still have a question?

If your situation is not covered here, you can share a brief outline of your project.

Request a Feasibility & Technical Risk Review

Get independent technical input on feasibility, risks, and next steps.